tradingkey.logo
tradingkey.logo

US FDA approves higher-dose of Biogen's genetic disorder drug

ReutersMar 30, 2026 11:34 AM

- The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's BIIB.O drug for a rare genetic disorder that causes progressive muscle weakness, offering patients a potentially more effective option, the company said on Monday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI